XML 15 R4.htm IDEA: XBRL DOCUMENT v3.21.2
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS) - USD ($)
shares in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Revenue        
Total revenue $ 222,057,000 $ 217,299,000 $ 437,128,000 $ 438,531,000
Expenses        
Cost of revenue (exclusive of depreciation and amortization expenses presented separately below) [1] 172,113,000 164,358,000 329,945,000 339,987,000
Selling, general and administrative expenses [1] 42,699,000 47,296,000 101,290,000 99,383,000
Depreciation and amortization expenses 14,916,000 15,618,000 30,103,000 31,596,000
Loss on disposal of assets 0 0 0 6,447,000
Goodwill impairment 0 215,100,000 0 215,100,000
Change in fair value of contingent consideration and indemnification asset 0 756,000 (594,000) (3,062,000)
Total operating expenses 229,728,000 443,128,000 460,744,000 689,451,000
Operating loss (7,671,000) (225,829,000) (23,616,000) (250,920,000)
Interest income 68,000 705,000 191,000 1,475,000
Interest expense (6,274,000) (6,290,000) (12,611,000) (12,571,000)
Impairment of equity method investments 0 0 0 (47,133,000)
Gain from equity method investees 4,879,000 25,143,000 12,662,000 24,731,000
Gain on transfer of membership 0 0 22,969,000 0
Loss on repayment of debt, net 0 0 (19,158,000) 0
Other income (expense), net (18,000) 354,000 (32,000) 284,000
Loss from continuing operations before income taxes (9,016,000) (205,917,000) (19,595,000) (284,134,000)
Provision (benefit) for income taxes 91,000 (3,904,000) 702,000 (3,634,000)
Loss from continuing operations (9,107,000) (202,013,000) (20,297,000) (280,500,000)
Income (loss) from discontinued operations, net of tax [2] 0 (1,508,000) 1,383,000 (1,773,000)
Net loss (9,107,000) (203,521,000) (18,914,000) (282,273,000)
Net loss attributable to non-controlling interests 0 0 0 0
Net loss attributable to common shareholders of Evolent Health, Inc. - Basic (9,107,000) (203,521,000) (18,914,000) (282,273,000)
Net loss attributable to common shareholders of Evolent Health, Inc. - Diluted $ (9,107,000) $ (203,521,000) $ (18,914,000) $ (282,273,000)
Loss per common share        
Continuing operations, basic (in dollars per share) $ (0.11) $ (2.37) $ (0.24) $ (3.30)
Continuing operations, diluted (in dollars per share) (0.11) (2.37) (0.24) (3.30)
Discontinued operations, basic (in dollars per share) 0 (0.01) 0.02 (0.02)
Discontinued operations, diluted (in dollars per share) 0 (0.01) 0.02 (0.02)
Basic loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share) (0.11) (2.38) (0.22) (3.32)
Diluted loss per share attributable to common shareholders of Evolent Health, Inc. (in dollars per share) $ (0.11) $ (2.38) $ (0.22) $ (3.32)
Weighted-average common shares outstanding        
Basic (in shares) 85,448 85,349 85,056 84,977
Diluted (in shares) 85,448 85,349 85,056 84,977
Comprehensive loss        
Net loss $ (9,107,000) $ (203,521,000) $ (18,914,000) $ (282,273,000)
Other comprehensive loss, net of taxes, related to:        
Foreign currency translation adjustment (58,000) (4,000) (89,000) (157,000)
Total comprehensive loss (9,165,000) (203,525,000) (19,003,000) (282,430,000)
Total comprehensive loss attributable to non-controlling interests 0 0 0 0
Total comprehensive loss attributable to common shareholders of Evolent Health, Inc. (9,165,000) (203,525,000) (19,003,000) (282,430,000)
Transformation services        
Revenue        
Total revenue [1] 2,564,000 755,000 2,909,000 5,993,000
Platform and operations services        
Revenue        
Total revenue [1] $ 219,493,000 $ 216,544,000 $ 434,219,000 $ 432,538,000
[1] See Note 19 for amounts attributable to unconsolidated related parties included in these line items.
[2] Includes $1.9 million gain on disposal of discontinued operations for the six months ended June 30, 2021